Omalizumab (Xolair) + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Steroid and/or Prednisone Dependent Asthma
Conditions
Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis
Trial Timeline
Mar 1, 2014 → Sep 1, 2017
NCT ID
NCT02049294About Omalizumab (Xolair) + Placebo
Omalizumab (Xolair) + Placebo is a phase 2/3 stage product being developed by Novartis for Steroid and/or Prednisone Dependent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT02049294. Target conditions include Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02049294 | Phase 2/3 | Completed |
| NCT01803763 | Phase 2/3 | Completed |
| NCT00851370 | Phase 2 | Withdrawn |
Competing Products
8 competing products in Steroid and/or Prednisone Dependent Asthma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Budesonide Nasal | Johnson & Johnson | Approved | 85 |
| Dapagliflozin + Sliding scale insulin | AstraZeneca | Approved | 85 |
| Ruxolitinib | Novartis | Approved | 85 |
| Ruxolitinib (RUX) + Best Available Therapy (BAT) | Novartis | Phase 3 | 77 |
| Rituximab | Roche | Phase 2 | 52 |
| Denosumab + Placebo for risendronate + Risendronate + Placebo for denosumab | Amgen | Phase 3 | 76 |
| Levetiracetam, Keppra | UCB | Approved | 82 |
| Itacitinib + Tocilizumab | Incyte | Phase 1 | 30 |